
Benzinga Pro data, Cara Therapeutics (NASDAQ:CARA) reported Q4 sales of $821.00 thousand. Earnings fell to a loss of $33.38 million, resulting in a 3195.36% decrease from last quarter. In Q3, Cara Therapeutics brought in $20.27 million in sales but lost $1.01 million in earnings.